| abstract |
The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1, 2, -dihydro-4- hydroxy-5-chloro-l-methyl-2-oxoquinoline-3-carboxanu.de or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl- 1, 2, -dihydro-4-hydroxy-5-chloro-l-methyl-2-oxoquinoline-3- carboxamide of 2-Chloro-6- ( l-ethyl-N-methyl-2-oxoindoline- 3-carboxamido) benzoic acid, IH, 3H-spiro [5-chloro-l- methylquinoline-2, 4-dione-3, 3' - [ 1] ethyl indol in- [2] -one], or 5-Chloro-Λ/-ethyl-3-hydroxy-l-methyl-2, 4-dioxo-Λ/-phenyl- 1,2,3, 4-tetrahydro-quinoline-3-carboxamide. |